Implantable device for the metronomic delivery of therapeutics for neuropathic disease mitigation

Cognos Therapeutics is pioneering advancements in therapeutic health through its innovative SINNAIS™ implantable smart pump technology, which integrates artificial intelligence (AI), blockchain, and cloud connectivity. This state-of-the-art device is designed for targeted and controlled delivery of therapeutics directly to the brain, significantly improving upon traditional intraventricular drug delivery methods. The SINNAIS™ pump utilizes a proprietary piezoelectric micropump capable of delivering precise 1 µL doses with ten times greater accuracy than existing implantable pumps. It features advanced capabilities such as real-time monitoring of cerebrospinal fluid (CSF) biomarkers, including beta-amyloid and tau proteins, which are critical in the treatment of neurological conditions like Alzheimer’s disease and various cancers. The device is also designed for long-term implantation, with a refillable reservoir and wireless communication for remote monitoring and programming.

Cognos Therapeutics is addressing significant unmet medical needs in the treatment of central nervous system (CNS) diseases and cancers, including Leptomeningeal carcinomatosis, pancreatic cancer, and glioblastoma. The SINNAIS™ technology not only enhances drug delivery precision but also introduces a fourth modality of continuous surveillance in cancer treatment, allowing for dynamic intervention based on real-time data. Collaborations with prestigious institutions like Harvard and Massachusetts General Hospital further bolster the clinical relevance of their innovations. By leveraging AI and blockchain, Cognos aims to personalize treatment regimens, improve patient outcomes, and ultimately reshape the landscape of therapeutic health.

United States

Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

Cognos Therapeutics

Company Details